ArticleNature reviews. Drug discovery2012
Defining rewardable innovation in drug therapy.
Article in Nature reviews. Drug discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Regulatory approval, reimbursement and postmarketing evidence of class 1 novel drugs in China, 2018-2023: an observational study.BMJ public health · 2026Article
- The Relationship between Health Insurance and Pharmaceutical Innovation: An Empirical Study Based on Meta-Analysis.Healthcare (Basel, Switzerland) · 2023Article
- Newly approved cancer drugs in China - innovation and clinical benefit.Nature reviews. Clinical oncology · 2023Article
- Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: Initial insights.Frontiers in medicine · 2022Article
- Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges.Expert opinion on drug discovery · 2021Article
- Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists.British journal of clinical pharmacology · 2020Review
- Using GRADE methodology to assess innovation of new medicinal products in Italy.British journal of clinical pharmacology · 2020Article
- Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areas.BMJ open · 2019Article
- Innovation as a value in healthcare priority-setting: the UK experience.Social justice research · 2019Article
- Patterns and predictors of physician adoption of new cardiovascular drugs.Healthcare (Amsterdam, Netherlands) · 2018Article
- Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Frontiers in pharmacology · 2017Review
- Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006-2015: a cohort study.European journal of clinical pharmacology · 2016Article
- Observational
- The most transformative drugs of the past 25 years: a survey of physicians.Nature reviews. Drug discovery · 2013Review
- Innovation in orthopaedic surgery as it relates to evidence-based practice.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2013Article
- Innovation and value-driven engineering.Nature reviews. Drug discovery · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Implementing mechanisms for rewarding those who introduce innovative medicinal products requires a definition of 'rewardable innovation'. Here, we propose a definition of innovation with respect to medicinal products, accompanied by a ranking of the importance of different types of innovativeness, with the aim of providing a basis for rewarding such innovation.
Indexed as
Identifiers
22460109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.